No biomarker
|
Hairy Cell Leukemia
|
No biomarker
|
Hairy Cell Leukemia
|
cladribine Sensitive: A1 - Approval
|
cladribine Sensitive: A1 - Approval
|
No biomarker
|
Hairy Cell Leukemia
|
No biomarker
|
Hairy Cell Leukemia
|
moxetumomab pasudotox Sensitive: A1 - Approval
|
moxetumomab pasudotox Sensitive: A1 - Approval
|
No biomarker
|
Hairy Cell Leukemia
|
No biomarker
|
Hairy Cell Leukemia
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
No biomarker
|
Hairy Cell Leukemia
|
No biomarker
|
Hairy Cell Leukemia
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
No biomarker
|
Hairy Cell Leukemia
|
No biomarker
|
Hairy Cell Leukemia
|
vemurafenib + rituximab Sensitive: A2 - Guideline
|
vemurafenib + rituximab Sensitive: A2 - Guideline
|
No biomarker
|
Hairy Cell Leukemia
|
No biomarker
|
Hairy Cell Leukemia
|
pentostatin Sensitive: A2 - Guideline
|
pentostatin Sensitive: A2 - Guideline
|
No biomarker
|
Hairy Cell Leukemia
|
No biomarker
|
Hairy Cell Leukemia
|
rituximab/hyaluronidase Sensitive: A2 - Guideline
|
rituximab / hyaluronidase Sensitive: A2 - Guideline
|
No biomarker
|
Hairy Cell Leukemia
|
No biomarker
|
Hairy Cell Leukemia
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
No biomarker
|
Hairy Cell Leukemia
|
No biomarker
|
Hairy Cell Leukemia
|
vemurafenib Sensitive: A2 - Guideline
|
vemurafenib Sensitive: A2 - Guideline
|
No biomarker
|
Hairy Cell Leukemia
|
No biomarker
|
Hairy Cell Leukemia
|
ibrutinib Sensitive: A2 - Guideline
|
ibrutinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Hairy Cell Leukemia
|
BRAF V600E
|
Hairy Cell Leukemia
|
dabrafenib Sensitive: C2 – Inclusion Criteria
|
dabrafenib Sensitive: C2 – Inclusion Criteria
|
BRAF V600
|
Hairy Cell Leukemia
|
BRAF V600
|
Hairy Cell Leukemia
|
vemurafenib Sensitive: C2 – Inclusion Criteria
|
vemurafenib Sensitive: C2 – Inclusion Criteria
|
BRAF V600E
|
Hairy Cell Leukemia
|
BRAF V600E
|
Hairy Cell Leukemia
|
vemurafenib Sensitive: C2 – Inclusion Criteria
|
vemurafenib Sensitive: C2 – Inclusion Criteria
|
BRAF V600E
|
Hairy Cell Leukemia
|
BRAF V600E
|
Hairy Cell Leukemia
|
dabrafenib + rituximab Sensitive: C3 – Early Trials
|
dabrafenib + rituximab Sensitive: C3 – Early Trials
|
TP53 mutation
|
Hairy Cell Leukemia
|
TP53 mutation
|
Hairy Cell Leukemia
|
rituximab + cladribine Resistant: C3 – Early Trials
|
rituximab + cladribine Resistant: C3 – Early Trials
|
MYD88 L265P + BRAF V600E
|
Hairy Cell Leukemia
|
MYD88 L265P + BRAF V600E
|
Hairy Cell Leukemia
|
rituximab Sensitive: C4 – Case Studies
|
rituximab Sensitive: C4 – Case Studies
|
KRAS mutation
|
Hairy Cell Leukemia
|
KRAS mutation
|
Hairy Cell Leukemia
|
vemurafenib Resistant: C4 – Case Studies
|
vemurafenib Resistant: C4 – Case Studies
|